Abstract: The present invention relates to biomedically useful compositions of C2-C3 linked polyethers of 1,6:2,3-dianhydrohexopyranose derivatives combined with effective amounts of one or more bioactive agents. In certain embodiments the C2-C3 linked polyether of a 1,6:2,3-dianhydrohexopyranose derivatives are aqueous insoluble. In certain other embodiments biomedically useful compositions have the physical form of microparticles, microspheres, tubes, rods, sheets, membranes, fibers and the like. In certain embodiments the bioactive agent is a protein.

Abstract: Provided is an orally disintegrating tablet coated with film that allows the time elapsed before a film thereof dissolves to be shorter, has a good feel when the tablet is taken, and is capable of being easily mass-produced. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature.

Abstract: This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.

Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.

Abstract: Medical devices with a hydrogel layer covalently attached to a portion of the outer surface of the medical device are provided along with methods for applying the coating. The hydrogel layer can include a first polymer species comprising polyethylene glycol (PEG) and a second polymer species. Examples of the second polymer species include PEG and polyacrylamide (PAM). The first and second species can be at least partially cross-linked. Methods for forming the hydrogel coatings on the medical devices are provided including nucleophilic conjugate reactions, such as Click reactions.

Abstract: The present invention relates to a liquid preparation for soft contact lenses, particularly hydrogel contact lenses or silicone hydrogel contact lenses. The liquid preparation for contact lenses according to the present invention contains a hydrolyzed hyaluronic acid derivative having a monoether of a linear or branched alkyl group or alkenyl group having 6 or more and 20 or less carbon atoms and glycerol in a side chain. The liquid preparation for soft contact lenses according to the present invention may contain at least one cationic bactericide selected from the group consisting of an alexidine salt, a chlorhexidine salt, a polyhexamethylene biguanide salt and a quaternary ammonium salt. The liquid preparation for soft contact lenses according to the present invention is capable of suppressing adsorption of a cationic bactericide to soft contact lenses, and suppressing occurrence of corneal staining in a wearer.

Abstract: Disclosed is a flexible substrate/liquid electrolyte viscous composite material and preparation method therefor. The preparation method includes: adding a particular percentage by weight of a flexible substrate to a liquid electrolyte solution having a particular concentrate; fully stirring the solution at a particular temperature to dissolve and evenly disperse the substrate, so as to obtain a viscous liquid; and then standing the viscous liquid at a particular temperature for a particular period of time to obtain the material. The material has viscosity due to which the material can actively adhere to the surface of tissue of an organ, the mechanical property matching cardiac muscle, biocompatibility and security, and is used for treating acute and chronic myocardial infarction and heart failures, inhibiting the reconstruction, thinning, and fiberization of a ventricular wall, and improving the myocardial function. In addition, the material also features conductivity, in vivo degradability, and the like.

Abstract: The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle.

Abstract: Personal care and household care compositions comprising a conditioner and rheology modifier based on a cationic galactomannan or cationic xyloglucan having cationic degree of substitution comprised between 0.01 and 3, free from (3-chloro-2-hydroxypropyl)trimethyl ammonium chloride and free from (2,3-epoxypropyl)trimethyl ammonium chloride.

Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.

Abstract: Ooids, microabrasive compositions containing ooids and methods of making microabrasive compositions containing ooids are described. Generally, ooids represent small particles, which are selectable for size, size distribution, and other characteristics and can be used as a microabrasive particle. Ooids generally show a high level of symmetry, sphericity, roundness and a low aspect ratio. As described here, these characteristics generally yield a predictable and highly effective abrasive.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: An effective dried attractive toxic bait station that acts as a lure and kill device for Ae. aegypti and other mosquitoes. The bait station is a simulated refuge at least part of which is coated with a dried mixture of poison and sugar forming a dried toxic sugar-containing bait. The simulated refuge attracts Ae. aegypti and other mosquitoes to bait station and encourages them to land on the coated portion. Once a mosquito has landed, it detects the sugar in the dried mixture of sugar and poison and ingests some of it. Once ingested, the dried mixture of poison and sugar will eventually kill the mosquito.

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystallized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).

Abstract: A formulation includes a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and a biologically active compound associated with the carrier agent.

Abstract: The present disclosure relates to the use of alkali metal salts and preferably lithium chloride for treatment of Varroa destructor infestation of honey bees.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.

Abstract: Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0° C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare therapeutical systems for the controlled-release of active principles through the transdermal route, thus solving stability, solubility and/or bioavailability problems of the active ingredient within the matrix.

Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Abstract: Provided are skin care compositions that are useful as SPF and UV absorption boosters in formulations containing inorganic metal oxides. The compositions comprise (a) 0.1 to 20 weight % inorganic metal oxide particles, based on the weight of the composition, wherein the inorganic metal oxide particles comprise ZnO and TiO2, and wherein the ratio of ZnO to TiO2 is from 1:10 to 10:1, (b) 0.1 to 15 weight % copolymer particles dispersed in an aqueous medium, wherein the copolymer particles comprise polymerized units derived from (i) 0.1 to 20 weight % of phosphorus acid monomers, and (ii) 80 to 99.9 weight % of comonomers, and (c) a dermatologically acceptable carrier. Also provided are methods of protecting skin from UVA and UVB damage comprising topically administering such compositions to the skin, and methods of boosting the SPF or UV absorption of a sunscreen composition containing inorganic metal oxide particles comprising including such copolymer particles in the composition.